X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs AJANTA PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA AJANTA PHARMA SANOFI INDIA/
AJANTA PHARMA
 
P/E (TTM) x 33.3 24.5 135.7% View Chart
P/BV x 6.3 10.1 62.7% View Chart
Dividend Yield % 1.4 0.6 239.9%  

Financials

 SANOFI INDIA   AJANTA PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
AJANTA PHARMA
Mar-16
SANOFI INDIA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5601,720 265.1%   
Low Rs4,4001,103 398.9%   
Sales per share (Unadj.) Rs1,028.5194.6 528.5%  
Earnings per share (Unadj.) Rs129.045.2 285.2%  
Cash flow per share (Unadj.) Rs186.050.3 369.8%  
Dividends per share (Unadj.) Rs68.008.00 850.0%  
Dividend yield (eoy) %1.50.6 267.8%  
Book value per share (Unadj.) Rs753.6132.0 570.8%  
Shares outstanding (eoy) m23.0388.77 25.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.47.3 60.1%   
Avg P/E ratio x34.731.2 111.3%  
P/CF ratio (eoy) x24.128.1 85.8%  
Price / Book Value ratio x5.910.7 55.6%  
Dividend payout %52.717.7 298.0%   
Avg Mkt Cap Rs m103,174125,299 82.3%   
No. of employees `0003.6NA-   
Total wages/salary Rs m3,5922,570 139.8%   
Avg. sales/employee Rs Th6,537.7NM-  
Avg. wages/employee Rs Th991.4NM-  
Avg. net profit/employee Rs Th819.8NM-  
INCOME DATA
Net Sales Rs m23,68617,275 137.1%  
Other income Rs m708166 425.7%   
Total revenues Rs m24,39417,442 139.9%   
Gross profit Rs m5,2815,807 90.9%  
Depreciation Rs m1,313451 291.4%   
Interest Rs m1549 30.7%   
Profit before tax Rs m4,6615,474 85.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6911,460 115.8%   
Profit after tax Rs m2,9704,014 74.0%  
Gross profit margin %22.333.6 66.3%  
Effective tax rate %36.326.7 136.0%   
Net profit margin %12.523.2 54.0%  
BALANCE SHEET DATA
Current assets Rs m15,6737,639 205.2%   
Current liabilities Rs m6,6782,715 246.0%   
Net working cap to sales %38.028.5 133.2%  
Current ratio x2.32.8 83.4%  
Inventory Days Days7643 175.8%  
Debtors Days Days2279 28.4%  
Net fixed assets Rs m8,0986,914 117.1%   
Share capital Rs m230177 130.2%   
"Free" reserves Rs m17,08811,442 149.3%   
Net worth Rs m17,35611,721 148.1%   
Long term debt Rs m0149 0.0%   
Total assets Rs m25,40014,814 171.5%  
Interest coverage x311.7112.9 276.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.91.2 80.0%   
Return on assets %11.827.4 42.8%  
Return on equity %17.134.2 50.0%  
Return on capital %26.946.5 57.9%  
Exports to sales %24.555.1 44.4%   
Imports to sales %28.06.0 465.8%   
Exports (fob) Rs m5,8019,527 60.9%   
Imports (cif) Rs m6,6271,038 638.7%   
Fx inflow Rs m7,14510,422 68.6%   
Fx outflow Rs m6,8461,678 407.9%   
Net fx Rs m2998,744 3.4%   
CASH FLOW
From Operations Rs m3,2263,264 98.8%  
From Investments Rs m-1,555-2,093 74.3%  
From Financial Activity Rs m-1,818-1,186 153.3%  
Net Cashflow Rs m-147-15 993.2%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 1.6 929.0%  
FIIs % 14.6 7.6 192.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.0 61.8%  
Shareholders   15,184 20,968 72.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 19, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS